Patents by Inventor Verity Margaret Sabin
Verity Margaret Sabin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8399483Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions, said substituted derivatives having the general formulaType: GrantFiled: December 17, 2008Date of Patent: March 19, 2013Assignee: UCB Pharma S.A.Inventors: Daniel Rees Allen, George Martin Buckley, Roland Bürli, John Richard Davenport, Natasha Kinsella, Christopher James Lock, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Andrew James Ratcliffe, Marianna Dilani Richard, Verity Margaret Sabin, Andrew Sharpe, Laura Jane Tait, Graham John Warrellow, Sophie Caroline Williams
-
Patent number: 8242116Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: GrantFiled: June 26, 2007Date of Patent: August 14, 2012Assignee: UCB Pharma S.A.Inventors: Rikki Peter Alexander, Pavandeep Singh Aujla, Karen Viviane Lucile Crépy, Anne Marie Foley, Richard Jeremy Franklin, Alan Findlay Haughan, Helen Tracey Horsley, William Mark Jones, Bénédicte Irma Léonce Frédérique Lallemand, Stephen Robert Mack, Trevor Morgan, Patrick Marie Ghislain Pasau, David Jonathan Phillips, Verity Margaret Sabin, George Martin Buckley, Kerry Jenkins, Benjamin Garfield Perry
-
Patent number: 8093238Abstract: A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).Type: GrantFiled: October 10, 2007Date of Patent: January 10, 2012Assignee: UCB Pharma S.A.Inventors: George Martin Buckley, Trevor Morgan, Verity Margaret Sabin
-
Publication number: 20110105508Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: December 17, 2008Publication date: May 5, 2011Applicant: UCB PHARMA, S.A.Inventors: Daniel Rees Allen, George Martin Buckley, Roland Bürli, John Richard Davenport, Natasha Kinsella, Christopher James Lock, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Andrew James Ratcliffe, Marianna Dilani Richard, Verity Margaret Sabin, Andrew Sharpe, Laura Jane Tait, Graham John Warrelow, Sophie Caroline Williams
-
Publication number: 20100137302Abstract: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: June 26, 2007Publication date: June 3, 2010Applicant: UCB PHARMA S.A.Inventors: Rikki Peter Alexander, Pavandeep Singh Aujla, Karen Viviane Lucile Crepy, Anne Marie Foley, Richard Jeremy Franklin, Alan Findlay Haughan, Helen Tracey Horsley, William Mark Jones, Benedicte Irma Leonce Frederique Lallemand, Stephen Robert Mack, Trevor Morgan, Patrick Marie Ghislain Pasau, David Jonathan Phillips, Verity Margaret Sabin, George Martin Buckley, Kerry Jenkins, Benjamin Garfield Perry
-
Publication number: 20100069361Abstract: A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).Type: ApplicationFiled: October 10, 2007Publication date: March 18, 2010Applicant: UCB PHARMA S.A.Inventors: George Martin Buckley, Trevor Morgan, Verity Margaret Sabin
-
Publication number: 20040176362Abstract: The invention relates to hydroxamic and carboxylic acid derivatives.Type: ApplicationFiled: March 17, 2004Publication date: September 9, 2004Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
-
Publication number: 20040122223Abstract: Nucleotide derivatives of formula (1) are described: wherein: G is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, aromatic or heteroaromatic group or a non-natural nucleoside as defined herein; G′ is a non-natural necleoside as defined herein; n is zero, or the integer 1 or 2; m is zero or the integer 1 or 2; and the salts, solvates, hydrates and N-oxides thereof. The compounds are P2Y receptor agonists and are of use in the prophylaxis and treatment of diseases and disorders involving abnormal secretory mechanisms such as inadequate functioning of mucociliary clearance mechanisms or abnormal tear secretion or in the treatment of diseases involving inappropriate cellular glucose uptake.Type: ApplicationFiled: January 15, 2004Publication date: June 24, 2004Inventors: Jeremy Martin Davis, Stephen Robert Mack, Verity Margaret Sabin, Richard John Davenport
-
Patent number: 6734189Abstract: The invention relates to hydroxamic and carboxylic acid derivatives. Compounds of the formula: are disclosed. These compounds are useful for the treatment of diseases mediated by inhibitors of matrix metalloproteinase, ADAM, ADAM-TS enzymes, and/or TNF&agr;-mediated diseases including degenerative diseases and certain cancers.Type: GrantFiled: September 6, 2002Date of Patent: May 11, 2004Assignee: Darwin Discovery, Ltd.Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
-
Publication number: 20030032652Abstract: The invention relates to hydroxamic and carboxylic acid derivatives.Type: ApplicationFiled: September 6, 2002Publication date: February 13, 2003Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
-
Patent number: 6469020Abstract: The invention relates to hydroxamic and carboxylic acid derivatives. Compounds of the formula: are disclosed. These compounds are useful for the treatment of diseases mediated by inhibitors of matrix metalloproteinase, ADAM, ADAM-TS enzymes, and or INF&agr;-mediated diseases including degenerative diseases and certain cancers.Type: GrantFiled: May 15, 2001Date of Patent: October 22, 2002Assignee: Darwin Discovery, Ltd.Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
-
Patent number: 6403791Abstract: A compound of the formula wherein R1 is C1-3 alkyl optionally substituted with one or more fluorines; R2 is C1-6 alkyl, cycloalkyl or NR4R5; R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C) NR4R5 is a nitrogen-containing heterocyclic ring; R6 is C1-3 alkyl; and R7 and R8, which are the same or different, each represents C1-3 alkyl, halogen, CF3 or CN; or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: February 9, 2001Date of Patent: June 11, 2002Assignee: Darwin Discovery, Ltd.Inventors: Hazel Joan Dyke, Alan Findlay Haughan, Christopher Lowe, George Martin Buckley, Richard John Davenport, Andrew Sharpe, Hannah Jayne Kendall, Verity Margaret Sabin, John Gary Montana, Catherine Louise Picken
-
Publication number: 20020013333Abstract: A pharmacologically active compound of formula (I) 1Type: ApplicationFiled: May 15, 2001Publication date: January 31, 2002Inventors: Duncan Batty, Verity Margaret Sabin, Robert John Watson, Hazel Joan Dyke, Andrew Sharpe, Richard John Davenport, David Alan Owen, Andrew Douglas Baxter
-
Patent number: 6313116Abstract: Compounds that are inhibitors of phosphodiesterase and have therapeutic utility, are of formula (i) wherein R1 is C3-6 cycoalkyl, or C1-3 alkyl optionally substituted with one or more fluorine atoms; R2 is C1-6 alkyl, C3-6 cycloalkyl, CF3, CH2CF3, C2F5 or NR4R5; R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C) NR4R5 is a nitrogen-containing heterocyclic ring; R6 is C1-3 alkyl; and R7 and R8, which are the same or different, are each H, C1-3 alkyl, halogen, CF3 or CN, provided that both are not H; or a pharmaceutically-acceptable salt thereofType: GrantFiled: February 9, 2001Date of Patent: November 6, 2001Assignee: Darwin Discovery, Ltd.Inventors: Hazel Joan Dyke, Andrew Sharpe, Hannah Jayne Kendall, Richard John Davenport, Verity Margaret Sabin, George Martin Buckley, Marianna Dilani Richard, Alan Findlay Haughan
-
Patent number: 6169090Abstract: The compound, according to formula (i) wherein X and Y are independently CH, N or N-oxide, provided that X and Y do not both represent CH; Z is CO or CS; R1 is alkyl, optionally substituted with one or more halogens; and R2, R3, R4 and R5 are each various organic groups. Such compounds have therapeutic utility, via inhibition of phosphodiesterase IV.Type: GrantFiled: June 8, 1999Date of Patent: January 2, 2001Assignee: Darwin Discovery, Ltd.Inventors: Hazel Joan Dyke, Verity Margaret Sabin, Andrew Sharpe, Alan Findlay Haughan, Christopher Lowe, George Buckley, John Montana
-
Patent number: 6069151Abstract: Compounds of the formula ##STR1## have therapeutic utility, as inhibitors of phosphodiesterase IV and TNF release.Type: GrantFiled: June 17, 1998Date of Patent: May 30, 2000Assignee: Darwin Discovery, Ltd.Inventors: Hazel Joan Dyke, John Gary Montana, Alan Findlay Haughan, Verity Margaret Sabin
-
Patent number: 6066657Abstract: A compound of formula (i) ##STR1## has therapeutic utility via inhibition of phosphodiesterase and THF release.Type: GrantFiled: February 9, 1999Date of Patent: May 23, 2000Assignee: Darwin Discovery, Ltd.Inventors: Hazel Joan Dyke, John Gary Montana, Christopher Lowe, Karen Ann Runcie, Alan Findlay Haughan, Verity Margaret Sabin, Duncan Hannah, Louise Picken, Andrew Sharpe
-
Patent number: 5804588Abstract: The subject invention concerns novel compounds of the general formula (i) ##STR1## that are useful in treating disease states, such as those states associated with proteins that mediate cellular activity. The compounds of the subject invention can be used, for example, to inhibit tumor necrosis factor and/or phosphodiesterase IV, The subject invention also concerns methods for treating disease states using the compounds of the invention.Type: GrantFiled: May 20, 1997Date of Patent: September 8, 1998Assignee: Chiroscience LimitedInventors: Hazel Joan Dyke, John Gary Montana, Christopher Lowe, Hannah Jayne Kendall, Verity Margaret Sabin